These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 25455490)
1. The effect of pK(a) on pyrimidine/pyridine-derived histamine H4 ligands. Savall BM; Meduna SP; Venable J; Wei J; Smith RC; Hack MD; Thurmond RL; McGovern P; Edwards JP Bioorg Med Chem Lett; 2014 Dec; 24(23):5489-92. PubMed ID: 25455490 [TBL] [Abstract][Full Text] [Related]
2. Diaminopyrimidines, diaminopyridines and diaminopyridazines as histamine H4 receptor modulators. Savall BM; Meduna SP; Tays K; Cai H; Thurmond RL; McGovern P; Gaul M; Zhao BP; Edwards JP Bioorg Med Chem Lett; 2015 Feb; 25(4):956-9. PubMed ID: 25595684 [TBL] [Abstract][Full Text] [Related]
3. Major advances in the development of histamine H4 receptor ligands. Smits RA; Leurs R; de Esch IJ Drug Discov Today; 2009 Aug; 14(15-16):745-53. PubMed ID: 19477292 [TBL] [Abstract][Full Text] [Related]
4. Piperazine modification in 2,4,6-triaminopyrimidine derivatives as histamine H4 receptor ligands. Schreeb A; Walter M; Odadzic D; Schwed JS; Weizel L; Stark H Pharmazie; 2013 Jul; 68(7):521-5. PubMed ID: 23923631 [TBL] [Abstract][Full Text] [Related]
5. A novel series of histamine H4 receptor antagonists based on the pyrido[3,2-d]pyrimidine scaffold: comparison of hERG binding and target residence time with PF-3893787. Andaloussi M; Lim HD; van der Meer T; Sijm M; Poulie CB; de Esch IJ; Leurs R; Smits RA Bioorg Med Chem Lett; 2013 May; 23(9):2663-70. PubMed ID: 23558237 [TBL] [Abstract][Full Text] [Related]
6. Histamine H4 receptor ligands and their potential therapeutic applications: an update. Kiss R; Keserű GM Expert Opin Ther Pat; 2012 Mar; 22(3):205-21. PubMed ID: 22385042 [TBL] [Abstract][Full Text] [Related]
7. Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist. Mowbray CE; Bell AS; Clarke NP; Collins M; Jones RM; Lane CA; Liu WL; Newman SD; Paradowski M; Schenck EJ; Selby MD; Swain NA; Williams DH Bioorg Med Chem Lett; 2011 Nov; 21(21):6596-602. PubMed ID: 21920751 [TBL] [Abstract][Full Text] [Related]
8. Novel histamine H4 receptor ligands and their potential therapeutic applications: an update. Kiss R; Keseru GM Expert Opin Ther Pat; 2014 Nov; 24(11):1185-97. PubMed ID: 25219452 [TBL] [Abstract][Full Text] [Related]
9. Agonist/antagonist modulation in a series of 2-aryl benzimidazole H4 receptor ligands. Savall BM; Edwards JP; Venable JD; Buzard DJ; Thurmond R; Hack M; McGovern P Bioorg Med Chem Lett; 2010 Jun; 20(11):3367-71. PubMed ID: 20452213 [TBL] [Abstract][Full Text] [Related]
10. Histamine H4 receptor ligands and their potential therapeutic applications. Kiss R; Keseru GM Expert Opin Ther Pat; 2009 Feb; 19(2):119-35. PubMed ID: 19441913 [TBL] [Abstract][Full Text] [Related]
11. Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands. Altenbach RJ; Adair RM; Bettencourt BM; Black LA; Fix-Stenzel SR; Gopalakrishnan SM; Hsieh GC; Liu H; Marsh KC; McPherson MJ; Milicic I; Miller TR; Vortherms TA; Warrior U; Wetter JM; Wishart N; Witte DG; Honore P; Esbenshade TA; Hancock AA; Brioni JD; Cowart MD J Med Chem; 2008 Oct; 51(20):6571-80. PubMed ID: 18811133 [TBL] [Abstract][Full Text] [Related]
12. 2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity. Hammer SG; Gobleder S; Naporra F; Wittmann HJ; Elz S; Heinrich MR; Strasser A Bioorg Med Chem Lett; 2016 Jan; 26(2):292-300. PubMed ID: 26718844 [TBL] [Abstract][Full Text] [Related]
13. Histamine H3 and H4 receptor affinity of branched 3-(1H-imidazol-4-yl)propyl N-alkylcarbamates. Łazewska D; Wiecek M; Ligneau X; Kottke T; Weizel L; Seifert R; Schunack W; Stark H; Kieć-Kononowicz K Bioorg Med Chem Lett; 2009 Dec; 19(23):6682-5. PubMed ID: 19846299 [TBL] [Abstract][Full Text] [Related]
14. Lead identification and optimization of diaminopyrimidines as histamine H4 receptor ligands. Sander K; Kottke T; Proschak E; Tanrikulu Y; Schneider EH; Seifert R; Schneider G; Stark H Inflamm Res; 2010 Mar; 59 Suppl 2():S249-51. PubMed ID: 20012148 [TBL] [Abstract][Full Text] [Related]
15. Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure. Watanabe M; Kazuta Y; Hayashi H; Yamada S; Matsuda A; Shuto S J Med Chem; 2006 Sep; 49(18):5587-96. PubMed ID: 16942032 [TBL] [Abstract][Full Text] [Related]
16. Pharmacological profile of astemizole-derived compounds at the histamine H1 and H4 receptor--H1/H4 receptor selectivity. Wagner E; Wittmann HJ; Elz S; Strasser A Naunyn Schmiedebergs Arch Pharmacol; 2014 Mar; 387(3):235-50. PubMed ID: 24241585 [TBL] [Abstract][Full Text] [Related]
17. Synthesis and functional characterization of imbutamine analogs as histamine H3 and H4 receptor ligands. Geyer R; Kaske M; Baumeister P; Buschauer A Arch Pharm (Weinheim); 2014 Feb; 347(2):77-88. PubMed ID: 24493592 [TBL] [Abstract][Full Text] [Related]